The Asia-Pacific Guidelines for the Treatment of Liver Diseases mentions the concept of drug discontinuation, for example, for patients with hepatitis B with major triplets, perhaps after the serological conversion of E antigen, the drug can be discontinued after one year of treatment, does this belong to the stage of clinical cure, can we say so? The course of antiviral treatment is described very clearly in the 05 Chinese guidelines for the prevention and treatment of chronic hepatitis B. The basic course of treatment for both E antigen-positive and negative patients is one year, and if at the end of the year E antigen-positive patients, let’s say, have a negative E antigen and E antibody, that is, E antigen serology conversion, then you can try to stop treatment for another year, that is, two years. Why? Because after one year of treatment for E antigen seroconversion, most patients are stable after stopping the drug, and only a small percentage of patients are relapsing. For patients who are E antigen negative, there is no such indicator as E antigen negative and serologic conversion, what about these patients? The course of treatment is one year, but if the transaminase level is normal and the HBV DNA level is undetectable, you can try to stop the drug after one and a half years of treatment. So the basic course of treatment for E antigen negative patients is 30 months, two and a half years, which is a basic course of treatment. For E antigen-positive patients, the percentage of E antigen serologic conversion for two years of treatment is not very high, so for the vast majority of patients the course of treatment should be more than two years, and for E antigen-negative patients two say the course of treatment is longer. So now there are guidelines for E antigen negative patients on antiviral therapy because there is no more E antigen negative and E antigen serologic conversion as an indicator to judge, so he can only judge the indicator on the surface antigen, and the rate of surface antigen negative is very very low, so that the course of treatment is very very long. There is some academic debate about how long oral nucleotide analog antiviral therapy is for patients with E antigen negative chronic hepatitis B. However, there is a consensus that long-term antiviral therapy should be administered.